Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$54.12M$54.12M+68.1% vs Q2 2023 Net Income-$70.41M-$70.41MN/M vs Q2 2023 EPS Diluted-$0.91-$0.91N/M vs Q2 2023 Operating Income-$67,704,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$40,325,000N/M Margins · derivedOperating margin-125.1%+197.8 pt vs Q2 2023
Net margin-130.1%+135.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 1, 2024 · 32 d after period end